Loading company…
Riskpilot
← Back to search
Sign in
Get full access
RexaCur AB
AB
Active
Org 5594262817
Datavägen 12 A
Wholesale of pharmaceutical and medical goods · NACE 4646
Est. 2023
1-4 employees
Watchlist
Share
Overview
Financials
People & ownership
Related companies
Revenue 2024
SEK 30,5M
+699% vs 2023
EBITDA margin
4.1%
+5732% vs 2023
Equity ratio
6.4%
Financial strength
Net profit 2024
SEK 698K
+10648% vs 2023
EBITDA — year on year
SEK millions
1M
1M
1M
0M
0M
0M
2023
1M
+100%
2024
Key figures
Annual report 2024
Revenue
SEK 30,5M
+699%
EBITDA
SEK 1,3M
+5732%
Net profit
SEK 698K
+10648%
Total assets
SEK 11,5M
+179%
Equity
SEK 730K
+2217%
Employees
—
—
Company information
Legal name
RexaCur AB
Org number
5594262817
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
15 mars 2023
Share capital
SEK 25 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska bedriva handel med läkemedel, apoteksvaror och därmed förenlig verksamhet.
Contact
Address
Datavägen 12 A
Email
info@rexacur.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Wholesale of pharmaceutical and medical goods
Companies in Kungsbacka
All Sweden companies
Revenue
SEK millions
0M
9M
17M
26M
35M
4M
2023
30M
2024
EBITDA
SEK millions
0M
0M
1M
1M
1M
0M
2023
1M
2024
Income statement
SEK thousands
Item
2023
2024
Revenue
3 815
30 468
Staff expenses
−8
−12
EBITDA
21
1 252
Depreciation & amort.
—
—
EBIT
21
1 252
Net financials
−13
−80
Profit before tax
8
880
Tax
−2
−181
Net profit
6
698
Balance sheet
SEK thousands
Item
2023
2024
Total assets
4 113
11 472
Equity
31
730
Long-term debt
622
425
Short-term debt
3 460
10 025
Total debt
4 082
10 450
Financial ratios
5-year trend
EBITDA margin
4.1%
This company
15.8%
Market median
-74% vs market
2023
2024
Equity ratio
6.4%
This company
38.2%
Market median
-83% vs market
2023
2024
Return on equity
95.7%
This company
18.4%
Market median
+420% vs market
2023
2024
Net profit margin
2.3%
This company
8.1%
Market median
-72% vs market
2023
2024
Asset turnover
2.66×
This company
1.12×
Market median
+138% vs market
2023
2024
Debt / equity
14.72×
This company
0.62×
Market median
-2274% vs market
2023
2024
Annual reports & filings
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-03-15 – 2023-12-31
View
PDF
Management
Actively employed in the business
Name
Role
Member since
Current (2)
CL
Carl Lennart Mathias Ljung
Audit
Audit
2025
MS
Malin Siv Ivanna Ekdahl
Chief Executive Officer
Chief Executive Officer
2023
Board of directors
Non-executive oversight
Name
Role
Member since
Current (2)
HA
Henrik Anders Karlsson
Chairman
2025
KM
Karin Maria Liljegren
Board of Directors
2025
Former (1)
EA
Emilie Aronsson Rindby
Deputy Board Member
2023 – 2025
Shareholders
As of last annual report
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
No registered parent or subsidiaries
Board network connections
Board members of RexaCur AB also hold positions in
0
other companies.
Person
Role here
Other companies
Carl Lennart Mathias Ljung
Audit
0 companies
Malin Siv Ivanna Ekdahl
Chief Executive Officer
0 companies
Henrik Anders Karlsson
Chairman
0 companies
Emilie Aronsson Rindby
Deputy Board Member
0 companies
Karin Maria Liljegren
Board of Directors
0 companies